Table 4 Associations between circulating biomarkers of inflammation and overall mortality according to patients and tumour characteristics among all participants (n = 306).

From: Association between post-treatment circulating biomarkers of inflammation and survival among stage II–III colorectal cancer patients

  

HR (95% CI)

Characteristics

Event/total

CRPa

IL-6a

MCP-1a

Adiponectina

Leptina

Overall

94/306

1.32 (1.1–1.59)

2.72 (2.07–3.56)

1.97 (1.18–3.28)

1.71 (1.14–2.58)

0.85 (0.7–1.03)

Sex

  Female

42/157

1.28 (0.93–1.76)

2.46 (1.61–3.76)

2.33 (1.2–4.53)

1.34 (0.77–2.34)

0.69 (0.51–0.93)

  Male

52/149

1.31 (1.03–1.65)

3.17 (2.23–4.5)

1.66 (0.69–3.98)

2.31 (1.23–4.35)

1 (0.76–1.32)

  Pinteraction

 

0.82

0.54

0.72

0.24

0.11

BMI

  Normal/Underweight

31/101

1.76 (1.28–2.42)

2.37 (1.6–3.53)

1.89 (0.66–5.43)

1.09 (0.46–2.59)

0.81 (0.58–1.14)

  Overweight

31/118

1.24 (0.9–1.72)

4.22 (2.3–7.75)

1.13 (0.33–3.95)

1.79 (0.88–3.61)

0.94 (0.65–1.37)

  Obese

32/87

0.94 (0.63–1.41)

2.3 (1.33–3.99)

2.69 (1.27–5.69)

2.08 (1.09–3.98)

0.66 (0.45–0.97)

  Pinteraction

 

0.02

0.13

0.94

0.37

0.82

Smoking status

  Ever-smoker

65/185

1.28 (1.03–1.59)

2.41 (1.73–3.35)

1.77 (0.98–3.2)

1.73 (1.05–2.88)

0.8 (0.64–1)

  Never-smoker

29/121

1.52 (1.01–2.28)

3.44 (1.92–6.15)

2.65 (0.77–9.18)

1.86 (0.86–4.02)

0.86 (0.57–1.32)

  Pinteraction

 

0.31

0.39

0.43

0.61

0.09

Stage at diagnosis

  II

42/143

1.3 (0.96–1.76)

2.48 (1.57–3.92)

1.44 (0.74–2.84)

1.91 (1.04–3.5)

0.88 (0.66–1.17)

  III

52/163

1.35 (1.05–1.73)

3.15 (2.18–4.56)

2.53 (1.08–5.94)

1.98 (1.09–3.62)

0.78 (0.59–1.03)

  Pinteraction

 

0.58

0.62

0.90

0.90

0.36

KRAS mutation

  Mutant

26/69

0.99 (0.65–1.52)

1.89 (1.03–3.48)

2.38 (0.4–14.16)

1.85 (0.71–4.81)

0.89 (0.59–1.33)

  Wild type

52/181

1.54 (1.2–1.98)

3.66 (2.35–5.69)

1.72 (0.91–3.27)

1.88 (1.11–3.2)

0.75 (0.59–0.97)

  Pinteraction

 

0.11

0.25

0.43

0.44

0.34

BRAF mutation

  Mutant

13/32

2.05 (1.11–3.8)

10.23 (2.46–42.45)

1.62 (0.25–10.6)

1.97 (0.6–6.45)

0.64 (0.36–1.15)

  Wild type

66/222

1.24 (0.99–1.55)

2.49 (1.73–3.58)

1.8 (0.98–3.31)

1.69 (1.04–2.74)

0.85 (0.68–1.08)

  Pinteraction

 

0.16

0.02

0.78

0.59

0.16

MSI

  MSI-higha

11/51

6.46 (2.04–20.49)

17.47 (3.59–85.09)

2.19 (0.39–12.47)

1.63 (0.4–6.68)

0.29 (0.13–0.68)

  MSS/MSI-low

63/189

1.16 (0.92–1.47)

1.94 (1.35–2.78)

1.88 (1–3.51)

1.74 (1.04–2.9)

0.85 (0.68–1.08)

  Pinteraction

 

0.007

0.02

0.47

0.63

0.02

CIMP

  High

17/41

1.25 (0.82–1.91)

5.63 (2.04–15.57)

3.56 (0.68–18.55)

4.9 (1.41–17.02)

0.4 (0.23–0.71)

  Low

55/171

1.27 (0.99–1.63)

2.64 (1.76–3.95)

1.82 (0.96–3.47)

1.48 (0.85–2.6)

0.78 (0.6–1)

 Pinteraction

 

0.52

0.23

0.64

0.32

0.06

Surgeryb

  Yes

79/284

1.36 (1.12–1.66)

2.45 (1.82–3.3)

1.91 (1.1–3.33)

1.93 (1.26–2.98)

0.78 (0.63–0.97)

  Pinteraction

 

Radiation

  Yes

27/73

1.21 (0.91–1.61)

1.9 (1.22–2.97)

1.09 (0.33–3.56)

1.54 (0.62–3.79)

0.64 (0.44–0.92)

  No

63/219

1.35 (1.07–1.71)

3.1 (2.16–4.46)

2.68 (1.32–5.44)

1.67 (1.04–2.69)

0.93 (0.72–1.19)

  Pinteraction

 

0.33

0.07

0.18

0.35

0.03

Chemotherapy

  Yes

70/241

1.38 (1.12–1.7)

2.89 (2.15–3.9)

2.09 (1.19–3.68)

1.47 (0.9–2.42)

0.72 (0.56–0.91)

  No

16/51

1.31 (0.83–2.08)

1.37 (0.62–3.02)

1.01 (0.23–4.47)

5.29 (1.68–16.63)

0.93 (0.56–1.57)

 Pinteraction

 

0.39

0.44

0.52

0.34

0.39

Tumour location

  Colom

61/212

1.35 (1.06–1.71)

3.36 (2.32–4.86)

2.85 (1.66–4.87)

1.67 (1.03–2.69)

0.76 (0.6–0.97)

  Rectum

32/93

1.21 (0.91–1.61)

1.82 (1.17–2.83)

0.35 (0.12–1.05)

2.21 (1–4.85)

0.9 (0.64–1.29)

  Pinteraction

 

0.11

0.03

0.0005

0.20

0.21

  1. aNatural log-transformed biomarkers: HRs per unit increase in natural logarithmic biomarker.
  2. bMore than 92% patients received surgery, we do not have enough statistical power to generate stable stratum-specific estimates for non-surgery group.